DERMATOMYOSITIS

This study planned to test deucravacitinib, a pill already approved for psoriasis, in adults with dermatomyositis or juvenile dermatomyositis that did not respond to standard treatments. The goal was to see if the drug could improve muscle and skin symptoms. However, the study wa…

This study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases called myositis. People who already took part in a previous study of this drug can join. They will receive the drug for up to 51 months and then be followed for 56 da…

This study tests an oral medication called brepocitinib in 241 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. Participants receive either the drug or a placebo for 52 weeks to see if it improves symptoms. The goal is to find a more effective …

This study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis leads to faster improvement than steroids alone. Myositis is a group of rare diseases that cause muscle inflammation and weakness. The trial includes 44 adults diagno…

This study tests a new medicine called empasiprubart against a placebo in adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. About 3 participants will receive the drug or placebo for 25 weeks, then be followed for safety over a year. The goal is …

This study examines blood samples from 50 adults with dermatomyositis, an autoimmune disease that affects muscles and skin and raises cancer risk. Researchers are searching for new antibodies and immune molecules that may explain why some patients develop cancer. The goal is to i…